Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016695 | 1.00 | EGFR (0.56) | EGFRAURKARPS6KB1 | |
| SCHEMBL22524283 | 1.00 | EGFR (0.56) | EGFRAURKARPS6KB1 | |
| SCHEMBL4572192 | 0.86 | RPS6KB1 (0.53) | EGFRAURKARPS6KB1 | |
| SCHEMBL4572186 | 0.86 | RPS6KB1 (0.53) | EGFRAURKARPS6KB1 | |
| SCHEMBL7780505 | 0.81 | RPS6KB1 (0.48) | AURKARPS6KB1 | |
| SCHEMBL7148659 | 0.81 | EGFR (0.42) | EGFRAURKARPS6KB1 | |
| SCHEMBL6016639 | 0.81 | EGFR (0.42) | EGFRAURKARPS6KB1 | |
| SCHEMBL6016698 | 0.80 | LMNA (0.66) | EGFRAURKARPS6KB1 | |
| SCHEMBL6016697 | 0.80 | LMNA (0.66) | EGFRAURKARPS6KB1 | |
| SCHEMBL5019518 | 0.79 | LMNA (0.64) | EGFRAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853616-B1 | BICYCLIC 4-ARALKYLAMINOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-19 | — | — | EP | claimed |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-0853616-B1 | BICYCLIC 4-ARALKYLAMINOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-19 | — | — | EP | disclosed |
| US-6057326-A | USED FOR TREATING EPIDERMAL HYPERPROLIFERATION, AS AN ANTI-METASTATIC OR ANTI-CANCER AGENT, TO CONTROL ANGIOGENESIS, INHIBIT DEVELOPMENT OF ATHEROMATOUS PLAQUE, TREATING ALZHEIMER'S DISEASE, OR AS AN IMMUNOMODULATING AGENT | PHARMACIA & UPJOHN S.P.A (IT) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | EGFR 4203/4885AURKA 2173/4885RPS6KB1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.